New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 1, 2014, Pages 69-77

  Medina, Miguel ^a   Avila, Jesús ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

Alzheimer; Dementia; DISC 1; GSK 3; Neurodegeneration; Neurogenesis; Schizophrenia

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; GLYCOGEN SYNTHASE KINASE 3; LITHIUM;

ALZHEIMER DISEASE; BRAIN; CELL STIMULATION; CELLULAR PARAMETERS; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; INTRACELLULAR SIGNALING; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SECOND MESSENGER; TIGHT JUNCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; BRAIN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; NEUROGENESIS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84890392083     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.843670     Document Type: Review

References (108)

1. Frame S, Cohen P, GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001;359(Pt 1):1-16
2. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001;65(4):391-426
3. Mukai F, Ishiguro K, Sano Y, Fujita SC. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 2002;81(5):1073-83
4. Schaffer B, Wiedau-Pazos M, Geschwind DH. Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3beta) in neural and non-neural tissues. Gene 2003;302(1-2):73-81
5. Medina M, Wandosell F. Deconstructing GSK-3: The Fine Regulation of Its Activity. Int J Alzheimers Dis 2011;2011:479249
6. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000;406(6791):86-90
7. O'Brien WT, Harper AD, Jove F, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004;24(30):6791-8
8. Kimura T, Yamashita S, Nakao S, et al. GSK-3beta is required for memory reconsolidation in adult brain. PLoS One 2008;3(10):e3540
9. Beaulieu JM, Zhang X, Rodriguiz RM, et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008;105(4):1333-8
10. Prickaerts J, Moechars D, Cryns K, et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: A putative model of hyperactivity and mania. J Neurosci 2006;26(35):9022-9
11. Latapy C, Rioux V, Guitton MJ, Beaulieu JM. Selective deletion of forebrain glycogen synthase kinase 3beta reveals a central role in serotonin-sensitive anxiety and social behaviour. Philos Trans R Soc Lond B Biol Sci 2012;367(1601):2460-74
12. MacAulay K, Doble BW, Patel S, et al. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab 2007;6(4):329-37
13. Kaidanovich-Beilin O, Lipina TV, Takao K, et al. Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain 2009;2:35
14. Hurtado DE, Molina-Porcel L, Carroll JC, et al. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci 2012;32(21):7392-402
15. Patel S, Macaulay K, Woodgett Jr. Tissue-specific analysis of glycogen synthase kinase-3alpha (GSK-3alpha) in glucose metabolism: Effect of strain variation. PLoS One 2011;6(1):e15845
16. Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci 2010;11(8):539-51
17. Medina M, Avila J. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des 2010;16(25):2790-8
18. Medina M, Garrido JJ, Wandosell FG. Modulation of GSK-3 as a therapeutic strategy on tau pathologies. Front Mol Neurosci 2011;4:24
19. Perez M, Hernandez F, Lim F, et al. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 2003;5(4):301-8
20. Maes M, Fisar Z, Medina M, et al. New drug targets in depression: Inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012;20(3):127-50
21. Li X, Jope RS. Is glycogen synthase kinase-3 a central modulator in mood regulatioñ Neuropsychopharmacology 2010;35(11):2143-54
22. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-Acting agents. Trends Neurosci 2012;35(1):47-56
23. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008;104(6):1433-9
24. Muyllaert D, Kremer A, Jaworski T, et al. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Genes Brain Behav 2008;7(Suppl 1):57-66
25. Hernandez F, Gomez de Barreda E, Fuster-Matanzo A, et al. GSK3: A possible link between beta amyloid peptide and tau protein. Exp Neurol 2010;223(2):322-5
26. Giese KP. GSK-3: A key player in neurodegeneration and memory. IUBMB Life 2009;61(5):516-21
27. Medina M, Avila J. Understanding the relationship between GSK-3 and Alzheimer's disease: A focus on how GSK-3 can modulate synaptic plasticity processes. Expert Rev Neurother 2013;13(5):495-503
28. Caricasole A, Copani A, Caraci F, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 2004;24(26):6021-7
29. Alarcon MA, Medina MA, Hu Q, et al. A novel functional low-density lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer's disease. Neurobiol Aging 2013;34(6):1709; e9-18
30. De Felice FG. Alzheimer's disease and insulin resistance: Translating basic science into clinical applications. J Clin Invest 2013;123(2):531-9
31. Jaworski T, Kugler S, Van Leuven F. Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis 2010;2010. doi: 10.4061/2010/573138
32. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005;102(19):6990-5
33. Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 2007;25(1):59-68
34. Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci USA 2006;103(23):8864-9
35. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 2009;8(10):783-93
36. Iqbal K, Liu F, Gong CX, et al. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009;118(1):53-69
37. De Strooper B, Vassar R, Golde T. The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010;6(2):99-107
38. Su Y, Ryder J, Li B, et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 2004;43(22):6899-908
39. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003;423(6938):435-9
40. Jaworski T, Dewachter I, Lechat B, et al. GSK-3alpha/beta kinases and amyloid production in vivo. Nature 2011;480(7376):E4-5; discussion E6
41. Tesco G, Tanzi RE. GSK3 beta forms a tetrameric complex with endogenous PS1-CTF/NTF and beta-catenin. Effects of the D257/D385A and FAD-linked mutations. Ann NY Acad Sci 2000;920:227-32
42. Palacino JJ, Murphy MP, Murayama O, et al. Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion. J Biol Chem 2001;276(42):38563-9
43. Twomey C, McCarthy JV. Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate. FEBS Lett 2006;580(17):4015-20
44. Baki L, Shioi J, Wen P, et al. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: Effects of FAD mutations. EMBO J 2004;23(13):2586-96
45. Rockenstein E, Torrance M, Adame A, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007;27(8):1981-91
46. Lee JH, Lau KF, Perkinton MS, et al. The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. J Biol Chem 2003;278(47):47025-9
47. Henriques AG, Vieira SI, da Cruz e Silva EF, da Cruz e Silva OA. Alphabeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures. J Mol Neurosci 2009;39(1-2):248-55
48. Christensen MA, Zhou W, Qing H, et al. Transcriptional regulation of BACE1, the beta-Amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 2004;24(2):865-74
49. Sun X, Wang Y, Qing H, et al. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 2005;19(7):739-49
50. Li Y, Zhou W, Tong Y, et al. Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. FASEB J 2006;20(2):285-92
51. Lammich S, Schobel S, Zimmer AK, et al. Expression of the Alzheimer protease BACE1 is suppressed via its 5'-untranslated region. EMBO Rep 2004;5(6):620-5
52. De Pietri Tonelli D, Mihailovich M, Di Cesare A, et al. Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. Nucleic Acids Res 2004;32(5):1808-17
53. Rogers GW Jr, Edelman GM, Mauro VP. Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. Proc Natl Acad Sci USA 2004;101(9):2794-9
54. Zhou W, Song W. Leaky scanning and reinitiation regulate BACE1 gene expression. Mol Cell Biol 2006;26(9):3353-64
55. Holsinger RM, McLean CA, Beyreuther K, et al. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 2002;51(6):783-6
56. Yang LB, Lindholm K, Yan R, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003;9(1):3-4
57. Fukumoto H, Rosene DL, Moss MB, et al. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 2004;164(2):719-25
58. Zhao J, Fu Y, Yasvoina M, et al. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer's disease pathogenesis. J Neurosci 2007;27(14):3639-49
59. Ly PT, Wu Y, Zou H, et al. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-Associated phenotypes. J Clin Invest 2013;123(1):224-35
60. Wyss-Coray T. Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nat Med 2006;12(9):1005-15
61. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010;129(2):154-69
62. Kaidanovich-Beilin O, Beaulieu JM, Jope RS, Woodgett Jr. Neurological functions of the masterswitch protein kinase - gsk-3. Front Mol Neurosci 2012;5:48
63. Beaulieu JM. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 2012;37(1):7-16
64. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res 2007;32(4-5):577-95
65. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-A brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012;2(1):a006346
66. Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007;282(46):33305-12
67. Magdesian MH, Carvalho MM, Mendes FA, et al. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 2008;283(14):9359-68
68. Parr C, Carzaniga R, Gentleman SM, et al. Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-beta precursor protein. Mol Cell Biol 2012;32(21):4410-18
69. Sofola O, Kerr F, Rogers I, et al. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet 2010;6(9):e1001087
70. Avrahami L, Farfara D, Shaham-Kol M, et al. Inhibition of glycogen synthase kinase-3 ameliorates beta-Amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: In vivo and in vitro studies. J Biol Chem 2013;288(2):1295-306
71. Caccamo A, Magri A, Medina DX, et al. mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer's disease and other tauopathies. Aging Cell 2013;12(3):370-80
72. Garthe A, Behr J, Kempermann G. Adult-generated hippocampal neurons allow the flexible use of spatially precise learning strategies. PLoS One 2009;4(5):e5464
73. Wiskott L, Rasch MJ, Kempermann G. A functional hypothesis for adult hippocampal neurogenesis: Avoidance of catastrophic interference in the dentate gyrus. Hippocampus 2006;16(3):329-43
74. Fabel K, Wolf SA, Ehninger D, et al. Additive effects of physical exercise and environmental enrichment on adult hippocampal neurogenesis in mice. Front Neurosci 2009;3:50
75. Winner B, Kohl Z, Gage FH. Neurodegenerative disease and adult neurogenesis. Eur J Neurosci 2011;33(6):1139-51
76. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4(11):1313-17
77. Arellano JI, Rakic P. Neuroscience: Gone with the wean. Nature 2011;478(7369):333-4
78. Sanai N, Nguyen T, Ihrie RA, et al. Corridors of migrating neurons in the human brain and their decline during infancy. Nature 2011;478(7369):382-6
79. Wang C, Liu F, Liu YY, et al. Identification and characterization of neuroblasts in the subventricular zone and rostral migratory stream of the adult human brain. Cell Res 2011;21(11):1534-50
80. Spalding KL, Bergmann O, Alkass K, et al. Dynamics of hippocampal neurogenesis in adult humans. Cell 2013;153(6):1219-27
81. Bergmann O, Liebl J, Bernard S, et al. The age of olfactory bulb neurons in humans. Neuron 2012;74(4):634-9
82. Lazarov O, Marr RA. Neurogenesis and Alzheimer's disease: At the crossroads. Exp Neurol 2010;223(2):267-81
83. Marlatt MW, Lucassen PJ. Neurogenesis and Alzheimer's disease: Biology and pathophysiology in mice and men. Curr Alzheimer Res 2010;7(2):113-25
84. Bossers K, Wirz KT, Meerhoff GF, et al. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain 2010;133(Pt 12):3699-723
85. Eom TY, Roth KA, Jope RS. Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3. J Biol Chem 2007;282(31):22856-64
86. Kim JS, Chang MY, Yu IT, et al. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo. J Neurochem 2004;89(2):324-36
87. Adachi K, Mirzadeh Z, Sakaguchi M, et al. Beta-catenin signaling promotes proliferation of progenitor cells in the adult mouse subventricular zone. Stem Cells 2007;25(11):2827-36
88. Mao Y, Ge X, Frank CL, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 2009;136(6):1017-31
89. Eom TY, Jope RS. Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation. Biol Psychiatry 2009;66(5):494-502
90. Luo Y, Shan G, Guo W, et al. Fragile x mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet 2010;6(4):e1000898
91. Guo W, Murthy AC, Zhang L, et al. Inhibition of GSK3beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum Mol Genet 2012;21(3):681-91
92. Kim WY, Wang X, Wu Y, et al. GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci 2009;12(11):1390-7
93. Fuster-Matanzo A, Llorens-Martin M, de Barreda EG, et al. Different susceptibility to neurodegeneration of dorsal and ventral hippocampal dentate gyrus: A study with transgenic mice overexpressing GSK3beta. PLoS ONE 2011;6(11):e27262
94. Sirerol-Piquer M, Gomez-Ramos P, Hernandez F, et al. GSK3beta overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus 2011;21(8):910-22
95. Fuster-Matanzo A, Llorens-Martin M, Sirerol-Piquer MS, et al. Dual effects of increased glycogen synthase kinase-3beta activity on adult neurogenesis. Hum Mol Genet 2013;22(7):1300-15
96. Llorens-Martin M, Fuster-Matanzo A, Teixeira CM, et al. GSK-3beta overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. Mol Psychiatry 2013;18(4):451-60
97. van Praag H, Kempermann G, Gage FH. Neural consequences of environmental enrichment. Nat Rev Neurosci 2000;1(3):191-8
98. Choi SH, Veeraraghavalu K, Lazarov O, et al. Non-cell-Autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 2008;59(4):568-80
99. Petrosini L, De Bartolo P, Foti F, et al. On whether the environmental enrichment may provide cognitive and brain reserves. Brain Res Rev 2009;61(2):221-39
100. Ackermann TF, Kempe DS, Lang F, Lang UE. Hyperactivity and enhanced curiosity of mice expressing PKB/SGKresistant glycogen synthase kinase-3 (GSK-3). Cell Physiol Biochem 2010;25(6):775-86
101. Lang UE, Borgwardt S. Molecular mechanisms of depression: Perspectives on new treatment strategies. Cell Physiol Biochem 2013;31(6):761-77
102. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996;93(16):8455-9
103. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-Term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. Br J Psychiatry 2011;198(5):351-6
104. Soares DC, Carlyle BC, Bradshaw NJ, Porteous DJ. DISC1: Structure, function, and therapeutic potential for major mental illness. ACS Chem Neurosci 2011;2(11):609-32
105. Wu Q, Li Y, Xiao B. DISC1-related signaling pathways in adult neurogenesis of the hippocampus. Gene 2013;518(2):223-30
106. Martinez A, Casto A, Medina M. Glycogen synthase kinase 3 (GSK-3) and its inhibitors: Drug discovery and development. John Wiley and Sons, Inc; Hoboken, New Jersey, USA: 2006
107. Ohm TG. The dentate gyrus in Alzheimer's disease. Prog Brain Res 2007;163:723-40
108. Paxinos G. The human nervous system. Elsevier Academic Press; San Diego, USA: 2004